Intercept Pharmaceuticals Inc (ICPT)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

10 HUDSON YARDS, 37TH FLOOR NEW YORK, NY 10001

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea.

Data as of 2020-11-22
Market Cap1.176 Billion Shares Outstanding32.992 Million Avg 30-day Volume938.865 Thousand
P/E Ratio-3.6 Dividend Yield EPS-9.8
Price/Sales3.909 Price cash flow ratio Price free cash flow ratio-5.4
Book Value-3.95 Price to Tangible Book-9.03 Alpha-0.03
Short Interest Ratio % Short Interest to Float R-squared0.189942
BETA1.83777 52-week High/Low125.0 / 27.0201 Stddev0.177698

Are you looking for this stock instead?

View SEC Filings from ICPT instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 5 (0.33%) 2 (0.13%) 150.0%
Funds Holding: 176 190 -7.37% 49 (3.22%) 51 (3.31%) -3.92%
13F shares: 28.225 Million 26.503 Million 6.5% 6.356 Million 6.118 Million 3.9%
% Ownership 85.5796 80.4522 6.37% 19.272 18.5704 3.78%
New Positions: 33 37 -10.81% 12 9 33.33%
Increased Positions 54 69 -21.74% 18 21 -14.29%
Closed Positions 44 29 51.72% 14 12 16.67%
Reduced Positions 52 51 1.96% 13 16 -18.75%
Total Calls 1.204 Million 1.468 Million -17.99% 265.1 Thousand 459.989 Thousand -42.37%
Total Puts 1.313 Million 1.691 Million -22.35% 799.7 Thousand 1.139 Million -29.8%
PUT/CALL Ratio 1.09 1.15 -5.22% 3.02 2.48 21.77%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ICPT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ICPT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WEYER CHRISTIAN EVP, RESEARCH & DEVELOPMENT

  • Officer
15,977 2020-11-27 11

DURSO JEROME BENEDICT CHIEF OPERATING OFFICER

  • Officer
38,784 2020-11-23 9

SULLIVAN RYAN T GENERAL COUNSEL AND SECRETARY

  • Officer
24,708 2020-11-13 6

CAWKWELL GAIL SVP, MED AFFAIRS, SAFETY & PV

  • Officer
21,297 2020-11-12 7

FORD DAVID A CHIEF HUMAN RESOURCES OFFICER

  • Officer
13,314 2020-11-08 10

PRUZANSKI MARK PRESIDENT & CEO

  • Officer
  • Director
575,517 2020-10-01 6

KAPADIA SANDIP CFO AND TREASURER

  • Officer
28,921 2020-10-01 5

KIM RICHARD J PRESIDENT US COMM & STRAT MKTG

  • Officer
20,828 2020-10-01 5

CAMPAGNA JASON CHIEF MEDICAL OFFICER

  • Officer
8,597 2020-10-01 13

GENEXTRA S.P.A.

4,000,000 2020-08-13 2

FUNDARO PAOLO

4,021,028 2020-08-13 3

MICHELI FRANCESCO

4,000,000 2020-08-13 2

BRIGHT LISA PRESIDENT, INTERNATIONAL

  • Officer
22,012 2020-07-01 4

AKKARAJU SRINIVAS

  • Director
426,809 2020-05-28 1

SBLENDORIO GLENN

  • Director
8,681 2020-05-28 1

BENATTI LUCA

  • Director
10,721 2020-05-28 1

WELCH DANIEL G

  • Director
8,060 2020-05-28 1

SANTINI GINO

  • Director
8,879 2020-05-28 1

GOTTESDIENER KEITH MICHAEL

  • Director
9,953 2020-05-28 1

BRADBURY DANIEL

  • Director
16,594 2020-05-28 1

MILLER-RICH NANCY

  • Director
7,538 2020-05-28 1

SHAPIRO DAVID CHIEF MEDICAL OFFICER

  • Officer
39,499 2019-05-01 0

BRIGHT LISA PRESIDENT, INTERNATIONAL

BRIGHT LISA PRESIDENT, INTERNATIONAL

  • Officer
18,807 2019-01-07 4

MCMINN RACHEL CHIEF STRATEGY OFFICER

  • Officer
16,875 2017-10-02 0

DUNCAN BARBARA GAYLE CHIEF ACCOUNTING OFFICER

  • Officer
30,661 2016-10-03 0

ADORINI LUCIANO SEE REMARKS

  • Officer
No longer subject to file 2016-02-01 0

VEITINGER KLAUS R DR

  • Director
2,816 2015-11-24 0

SILVERSTEIN JONATHAN

  • Director
1,121,583 2015-11-24 0

WILLIAMS NICOLE

  • Director
962 2015-11-20 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • Director
1,120,609 2015-07-17 0

REGAN DANIEL PAUL CHIEF COMMERCIAL OFFICER

  • Officer
1,264 2015-01-30 0

PATEL SANJ K

  • Director
452 2014-07-17 0

TALLARIGO LORENZO

  • Director
0 2014-07-07 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WEYER CHRISTIAN - Officer EVP, RESEARCH & DEVELOPMENT

2020-11-30 19:00:23 -0500 2020-11-27 F 357 $37.27 d 15,977 direct 2.5778 2.5778 2 0.0 1

DURSO JEROME BENEDICT - Officer CHIEF OPERATING OFFICER

2020-11-25 19:00:18 -0500 2020-11-23 F 319 $35.47 d 38,784 direct -4.7223 0.0 1 -4.7223 2

SULLIVAN RYAN T - Officer GENERAL COUNSEL AND SECRETARY

2020-11-16 19:00:41 -0500 2020-11-13 F 493 $37.87 d 24,708 direct -2.759 -5.2317 0.0 1 -7.6783 5

CAWKWELL GAIL - Officer SVP, MED AFFAIRS, SAFETY & PV

2020-11-16 19:00:21 -0500 2020-11-12 F 319 $38.52 d 21,297 direct -2.759 -5.2317 0.0 1 -7.6783 5

FORD DAVID A - Officer CHIEF HUMAN RESOURCES OFFICER

2020-11-10 19:00:16 -0500 2020-11-08 F 128 $28.15 d 13,314 direct -1.9099 -4.8638 0.0 1 -4.8638 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments